Novo Nordisk announced in February that from 1 January 2027 it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month — a reduction of roughly 50% for Wegovy and 35% for Ozempic. It is a genuinely large number and it made a lot of headlines. For most people reading this, it will change nothing about what they pay, and it is worth understanding why before deciding it is good news.
What list price is, and who pays it
List price — wholesale acquisition cost — is the published sticker price before any rebate or negotiation. Almost nobody pays it. Insurers and pharmacy benefit managers negotiate down from it, and manufacturers sell to them at a discount that is not disclosed. The list price is the starting point of a negotiation most patients never see.
The people for whom it does matter are those whose out-of-pocket cost is calculated from list: patients on high-deductible plans paying the full negotiated rate until the deductible is met, and those on co-insurance who pay a percentage rather than a flat copay. Novo’s own announcement names exactly this group. If you are one of them, a 50% cut to the reference figure is real money.
It is also worth knowing what the $675 covers, because it is a named list rather than a blanket cut: Wegovy injection at 2.4 mg and tablets at 25 mg, Ozempic injection at 0.5 mg, 1 mg and 2 mg, and Rybelsus tablets at 7 mg and 14 mg. Those are the maintenance strengths — the doses people settle on rather than the ones they start at. Novo describes the decision as applying to all doses of these medicines, but the strengths enumerated in the announcement are the higher ones, which is where the list price was highest to begin with.
Why it does not reach cash payers
Novo has said explicitly that the change does not affect direct-to-patient self-pay pricing. That is the channel most uninsured buyers now use, and its prices sit well below $675 already — $349 a month for the standard Wegovy pen and $149 for the cheapest tablet dose, as our pricing breakdown sets out. A list price falling to $675 does not touch a $349 self-pay price. If anything it narrows a gap that had become conspicuous.
The sequence is worth noting. Novo moved cash Wegovy to $499 a month, then Ozempic to $499, then launched a $199 introductory self-pay offer, and is now bringing the list price down to $675. Each step narrowed the distance between the official price and the one people were actually being charged. The list price cut is the last and largest of those adjustments, and also the one that reaches the fewest people directly.
What to watch
The change does not take effect until January 2027, so nothing moves for four months. Whether insured patients see the benefit depends on how plans and benefit managers respond — a lower list price with correspondingly smaller rebates can leave net cost to the plan unchanged, which is a familiar outcome in US drug pricing. Novo has not published what happens to rebate levels, and it is not obliged to.
The short version: if your costs are tied to list price, check your plan again in January. If you are paying cash, this announcement is not about you.
